Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

Many tyrosine kinase-driven cancers, including chronic myeloid leukemia (CML), are characterized by high response rates to specific tyrosine kinase inhibitors (TKIs) like imatinib. In East Asians, primary imatinib resistance is caused by a deletion polymorphism in Intron 2 of the BIM gene, whose pro...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Liu, Jun, Bhadra, Malini, Sinnakannu, Joanna Rajeswary, Yue, Wan Lin, Tan, Cheryl Weiqi, Rigo, Frank, Ong, S.Tiong, Roca, Xavier
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652800/
https://ncbi.nlm.nih.gov/pubmed/29100409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20658
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы